|
ACS Nano
|
1 |
0.10 |
|
|
|
American Journal of Human Genetics
|
1 |
1.00 |
|
|
|
American Journal of Pathology
|
2 |
2.00 |
|
|
|
American Journal of Respiratory and Critical Care Medicine
|
4 |
2.88 |
|
|
|
Analytical Chemistry
|
2 |
1.86 |
|
|
|
Anesthesiology
|
2 |
2.00 |
|
|
|
Angewandte Chemie International Edition
|
2 |
1.77 |
|
|
|
Annals of Internal Medicine
|
1 |
0.04 |
|
|
|
Annals of Neurology
|
1 |
0.04 |
|
|
|
Annals of Surgery
|
6 |
2.34 |
|
|
|
Annals of the Rheumatic Diseases
|
5 |
2.15 |
|
|
|
Applied Physics Letters
|
1 |
1.00 |
|
|
|
Archives of Physical Medicine and Rehabilitation
|
5 |
5.00 |
|
|
|
Arthritis & Rheumatology
|
11 |
5.18 |
|
|
|
Brain
|
2 |
1.18 |
|
|
|
Cancer Cell
|
1 |
0.12 |
|
|
|
Cell Metabolism
|
1 |
0.03 |
|
|
|
Cell Stem Cell
|
1 |
1.00 |
|
|
|
Circulation
|
2 |
0.16 |
|
|
|
Clinical Infectious Diseases
|
2 |
1.06 |
|
|
|
Computers in Human Behavior
|
1 |
1.00 |
|
|
|
Critical Care Medicine
|
13 |
11.66 |
|
|
|
Current Biology
|
4 |
2.58 |
|
|
|
Diabetes Care
|
2 |
1.07 |
|
|
|
Environmental Health Perspectives
|
1 |
1.00 |
|
|
|
Environmental Research
|
3 |
1.06 |
|
|
|
European Heart Journal
|
4 |
0.26 |
|
|
|
European Urology
|
1 |
0.00 |
|
|
|
Gut
|
5 |
1.17 |
|
|
|
Hepatology
|
4 |
0.16 |
|
|
|
Immunity
|
1 |
0.15 |
|
|
|
Inorganic Chemistry
|
1 |
0.13 |
|
|
|
International Journal of Epidemiology
|
1 |
1.00 |
|
|
|
International Journal of Obesity
|
2 |
1.96 |
|
|
|
JAMA Internal Medicine
|
1 |
0.29 |
|
|
|
JAMA Psychiatry
|
1 |
0.11 |
|
|
|
JAMA Surgery
|
1 |
0.44 |
|
|
|
JAMA: The Journal of the American Medical Association
|
3 |
1.11 |
|
|
|
Journal of Biological Chemistry
|
7 |
5.93 |
|
|
|
Journal of Bone and Joint Surgery-American Volume
|
8 |
6.47 |
|
|
|
Journal of Cleaner Production
|
1 |
0.10 |
|
|
|
Journal of Clinical Endocrinology & Metabolism
|
17 |
15.31 |
|
|
|
Journal of Clinical Investigation
|
3 |
0.71 |
|
|
|
Journal of Hepatology
|
4 |
0.87 |
|
|
|
Journal of Infectious Diseases
|
4 |
2.97 |
|
|
|
Journal of Neuroscience
|
8 |
5.33 |
|
|
|
Journal of Physiology
|
3 |
3.00 |
|
|
|
Journal of Thoracic and Cardiovascular Surgery
|
6 |
5.85 |
|
|
|
Journal of the American Academy of Dermatology
|
1 |
0.06 |
|
|
|
Journal of the American Chemical Society
|
1 |
1.00 |
|
|
|
Journal of the American College of Cardiology
|
2 |
1.04 |
|
|
|
Journal of the American Geriatrics Society
|
5 |
4.29 |
|
|
|
Journal of the American Society of Nephrology
|
6 |
3.82 |
|
|
|
Kidney International
|
2 |
0.96 |
|
|
|
Molecular Psychiatry
|
12 |
7.21 |
|
|
|
Nature
|
4 |
2.02 |
|
|
|
Nature Communications
|
38 |
23.51 |
|
|
|
Nature Genetics
|
1 |
0.02 |
|
|
|
Nature Immunology
|
2 |
0.04 |
|
|
|
Nature Medicine
|
4 |
0.13 |
|
|
|
Nature Neuroscience
|
1 |
0.04 |
|
|
|
Neuron
|
2 |
1.33 |
|
|
|
PLOS Biology
|
1 |
0.82 |
|
|
|
PLOS Genetics
|
2 |
0.20 |
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
|
18 |
13.13 |
|
|
|
Radiology
|
1 |
0.08 |
|
|
|
Science
|
2 |
0.70 |
|
|
|
Science Advances
|
8 |
4.54 |
|
|
|
Science Translational Medicine
|
3 |
0.16 |
|
|
|
Sustainable Cities and Society
|
1 |
1.00 |
|
|
|
The BMJ
|
1 |
1.00 |
|
|
|
The EMBO Journal
|
1 |
1.00 |
|
|
|
The Journal of Allergy and Clinical Immunology
|
7 |
3.14 |
|
|
|
The Lancet
|
6 |
0.30 |
|
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial
|
0.05 |
|
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial
|
0.05 |
|
Maternal and neonatal outcomes after infection with monkeypox virus clade I during pregnancy in DR Congo: a pooled, prospective cohort study
|
0.01 |
|
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials
|
0.03 |
|
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
|
0.05 |
|
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial
|
0.11 |
|
|
The Lancet Diabetes & Endocrinology
|
4 |
0.30 |
|
Safety, tolerability, pharmacokinetics, and efficacy of burosumab in infants with X-linked hypophosphataemia: an open-label, multicentre, non-randomised study
|
0.07 |
|
Association of gestational thyroid function and thyroid autoimmunity with gestational diabetes: a systematic review and individual participant meta-analysis
|
0.03 |
|
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
|
0.10 |
|
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial
|
0.10 |
|
|
The Lancet Psychiatry
|
1 |
0.09 |
|
|
|
The New England Journal of Medicine
|
5 |
0.42 |
|
|
|
Thorax
|
2 |
2.00 |
|
|
|
Water Research
|
2 |
1.14 |
|
|